Table 1.

Patient demographics and prior treatment information

Demographics and clinical data
Median age, years (range)	53 (28–70)
Race, White	26/31 (84%)
Black/other	5/31 (16%)
Stage at breast cancer diagnosis, 0–III	19 (59%)
IV	13 (41%)
Median Time since first brain metastases (years)	1.12 (0.4–6.5)
Prior systemic chemotherapy (metastatic)	30 (94%)
Prior metastatic lines, # (range)	2 (0–7)
Prior anti-HER2 (metastatic)	30 (94%)
Trastuzumab	29/30 (97%)
Lapatinib	22/30 (73%)
Pertuzumab	12/30 (40%)
TDM-1	8/30 (27%)
Prior CNS local therapy
Surgery	10/31 (32%)
Any CNS RT	31/32 (97%)
WBRT	22/32 (69%)
SRS	17/32 (53%)
Median time since CNS RT (days) (n = 31)	237 (IQR 135–392) (range: 12–1911)
CNS RT within 12 weeks of starting treatment	2 (6%)
Recursive partitioning analysis score (1, 2, or 3)	10 (31%), 21 (65%), 3 (3%)
Steroid use at baseline	10 (31%)
Extracranial disease at enrollment	20 (63%)